Drugs / Interferon-beta
Interferon-beta
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT00789685 | Feb 2009 → Sep 2011 | acute lung injury, acute respiratory distress syndrome | Faron Pharmaceuticals Ltd | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT01171209 | Jul 2010 → Jun 2011 | multiple sclerosis | Melinda Magyari | Completed | No outcome recorded |
| Phase 2 | NCT00085306 | Apr 2004 → Oct 2007 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT04324463 | Apr 2020 → Dec 2022 | severe acute respiratory syndrome | Population Health Research Institute | Completed | Missed primary |
| Phase 3 | NCT00344253 | Mar 2006 → Mar 2011 | intermediate uveitis, macular retinal edema, multiple sclerosis | Heidelberg University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00004450 | Aug 1998 → Nov 2000 | adrenoleukodystrophy | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02903537 Background | Jul 2017 → Dec 2023 | chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis | Germans Trias i Pujol Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT06715605 Comparator | Apr 2025 | multiple sclerosis | University Hospital, Antwerp | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 27
| Date | Issuer | Release |
|---|---|---|
| 2022-12-23 | Synairgen Research Ltd. | Results SPRINTER Trial Results Published synairgen.com ↗
Topline results from this global, double-blind, placebo-controlled trial were first shared in February 2022, with the data analysis presented at the American Thoracic Society International Conference in San Francisco in May 2022. |
| 2022-10-26 | Biogen | Results New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS biogen.com ↗
Data on interferon exposure during pregnancy showed that treatment with PLEGRIDY ® (peginterferon beta-1a) or AVONEX ® (interferon beta-1a) did not negatively impact child development |
| 2022-10-04 | Synairgen Research Ltd. | Results Data from the US NIH-led ACTIV-2 Phase 2 trial synairgen.com ↗
Fewer participants required hospitalisation following treatment with SNG001 (N=1/110, [1%]) compared to placebo (N=7/110, [6%]), an 86% relative risk reduction, that was not statistically significant (P=0.07; two-sided Fisher's exact test). |
| 2022-09-20 | Synairgen Research Ltd. | Results SPRINTER Long COVID data presented at IDWeek synairgen.com ↗
The analysis shows that when compared to placebo, SNG001 reduced the relative risk of recognised symptoms of Long COVID at day 60 and/or day 90: |
| 2022-09-13 | Faron Pharmaceuticals Ltd | Results Traumakine Data Presented at MHSR Symposium faron.com ↗
Primates treated with Traumakine at the time of major inflammation due to ischemia showed lower levels of muscle and liver damage markers indicating total body protection |
| 2022-05-16 | Synairgen Research Ltd. | Results Synairgen presents at ATS 2022 synairgen.com ↗
Post hoc analyses conducted in patient populations at greater risk of progression to severe disease or death suggests that SNG001 may have an important clinical effect on top of standard of care |
| 2022-03-14 | Faron Pharmaceuticals Ltd | Results Faron Publishes Research From INTEREST Trial faron.com ↗
A post hoc genetic analysis by the Company found that patients receiving Traumakine and carrying the SNP rs9984273 (C/T) in subunit 2 of INFAR2 showed a substantial reduction in mortality compared to patients without the gene mutation. |
| 2022-02-21 | Synairgen Research Ltd. | Results Topline results from Phase 3 SPRINTER trial synairgen.com ↗ |
| 2022-02-03 | Faron Pharmaceuticals Ltd | Results Scientific Reports Publishes INFORAAA Results faron.com ↗
today announces that the multidisciplinary journal Scientific Reports from the Nature Publishing Group published research highlighting results from Faron’s Phase II INFORAAA clinical trial. |
| 2021-01-26 | Faron Pharmaceuticals Ltd | Regulatory Update on TRAUMAKINE development faron.com ↗ |
| 2020-10-16 | Faron Pharmaceuticals Ltd | Results First Results from WHO Solidarity Trial faron.com ↗
The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalized patients with COVID-19. |
| 2020-05-20 | Faron Pharmaceuticals Ltd | Results Faron Pharmaceuticals Oy Harmful association of glucocorticoids in interferon beta-1a treated patients published in Intensive Care Medicine faron.com ↗
The results showed that the desired mechanism of action of IV IFN beta-1a in the lung vasculature – the upregulation of CD73 – is blocked by the administration of glucocorticoids. |
| 2020-03-09 | Faron Pharmaceuticals Ltd | Regulatory FDA accepts protocol for new Traumakine trial faron.com ↗
FDA accepts protocol for new Traumakine trial |
| 2019-06-14 | Faron Pharmaceuticals Ltd | Results Final results from YODA study faron.com ↗
The concomitant use of IFN beta-1a and prednisolone during part III reduced IFN beta-1a action, compared to subjects who received IFN beta-1a alone. |
| 2018-12-19 | Faron Pharmaceuticals Ltd | Results Traumakine update – YODA results faron.com ↗
YODA trial results from the first 30 subjects indicate that IFN-beta, regardless of the method of solubilisation, produced the expected level of bioactivity suggesting that drug formulation was not a factor in the outcome of the INTEREST trial. |
| 2018-12-05 | Faron Pharmaceuticals Ltd | Results Patient subgroup identified from INTEREST trial faron.com ↗
The D28 overall mortality of this group was 11.1% despite receiving, or not receiving, concurrent steroids. |
| 2018-10-22 | Faron Pharmaceuticals Ltd | Results INTEREST trial update presented at ESICM faron.com ↗ |
| 2018-06-18 | Merck KGaA, Darmstadt, Germany | Results Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS prnewswire.com ↗
Furthermore, additional post hoc data from clinical studies of patients treated with Rebif (subcutaneous interferon beta-1a) showed that the MAGNIMS score at Year 1 reliably predicted long-term clinical disease activity (CDA)-free status and disability progression. |
| 2018-06-14 | Faron Pharmaceuticals Ltd | Results Biomarker analysis of Phase III INTEREST trial faron.com ↗ |
| 2018-05-11 | Faron Pharmaceuticals Ltd | Results Update on the Phase III INTEREST trial faron.com ↗
Early analysis of certain biomarker indicators suggest that the treatment did not produce the expected interferon-beta bioactivity in the treatment group that was previously seen in Faron’s Phase I/II trial for Traumakine. |
| 2017-10-27 | Hoffmann-La Roche | Results New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis roche.com ↗
OCREVUS significantly reduced the proportion of people with RMS who experienced Progression Independent of Relapse Activity (PIRA) in a post-hoc analysis compared to Rebif® (interferon-beta 1a). |
| 2016-01-07 | Faron Pharmaceuticals Ltd | Results Top-line results from Japanese study of Traumakine faron.com ↗
The all-cause mortality rate at Day 28, being the primary efficacy end point, was 22.2% across all patients (4/18). |
| 2014-06-16 | Biogen | Results Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis biogen.com ↗
Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). |
| 2014-05-01 | Biogen | Results New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients biogen.com ↗
Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFNβ) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. |
| 2013-03-18 | Biogen | Results ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status biogen.com ↗
TYSABRI demonstrated a significantly lower rate of first relapse compared to interferon beta (IFN) and glatiramer acetate (GA). |
| 2010-05-17 | Synairgen Research Ltd. | Results New data for the treatment of “severe‟ influenza lung infection synairgen.com ↗ |
| 2009-04-15 | Biogen | Results Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology biogen.com ↗
Another presentation will include further evidence on the potential mechanism of action of AVONEX ( Interferon-beta Treatment Increases FoxP3 Expression and CD56 bright Natural Killer Cells in Subjects with Multiple Sclerosis – S06.001 ). |
All press releases naming this drug 29 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon beta | “Standard-of-care on first-line treatment such as interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod and ozanimod.” NCT06715605 ↗ |
| Known as | IFN β-1a | “This was a phase I/II open-label study to assess the safety, tolerability and preliminary efficacy of FP-1201 (IFN β-1a) in the treatment of patients with ALI and ARDS.” NCT00789685 ↗ |
| Known as | IFN-β | “A major problem in the treatment of multiple sclerosis (MS) patients with interferon-beta (IFN-β) is the development of neutralising antibodies (NAbs).” PMID 25877635 ↗ Dec 2012 |
| Known as | interferon-beta-1a | “The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.” PMID 24503265 ↗ Dec 2013 |
| Modality | Protein / enzyme biologic | “Biological: recombinant interferon beta” NCT00085306 ↗ |
| Route | Subcutaneous | “interferon beta by subcutaneous injection” NCT00004450 ↗ |